Docetaxel
- Generic Name
- Docetaxel
- Brand Names
- Taxotere, Docetaxel Accord, Docetaxel Kabi
- Drug Type
- Small Molecule
- Chemical Formula
- C43H53NO14
- CAS Number
- 114977-28-5
- Unique Ingredient Identifier
- 699121PHCA
- Background
Docetaxel is a clinically well established anti-mitotic chemotherapy medication used for the treatment of different types of cancer, including breast, ovarian, and non-small cell lung cancer. Docetaxel is a complex diterpenoid molecule and a semisynthetic analogue of paclitaxel. Docetaxel reversibly binds to microtubulin with high affinity in a 1:1 stoichiom...
- Indication
Docetaxel is indicated as a single agent for the treatment of locally advanced or metastatic breast cancer after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC. It is also indicated as a single agent for locally advanced or metastatic non-small cell lung cancer (NSCLC) after platinum therapy...
- Associated Conditions
- Esophageal Cancer, Ewing's Sarcoma, Locally Advanced Breast Cancer (LABC), Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Node Positive Breast Cancer, Ovarian Cancer Metastatic, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Advanced untreated gastric adenocarcinoma, Locally advanced Squamous cell carcinoma of head and neck, Locally advanced untreated non small cell lung cancer, Metastatic untreated non small cell lung cancer, Refractory, locally advanced Non small cell lung cancer, Refractory, metastatic Non small cell lung cancer, Refractory, metastatic hormone-refractory Prostate cancer
- Associated Therapies
- -
Phase 3 Clinical Trial Of ANKTIVA Plus NIVOLUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 460
- Registration Number
- NCT06745908
Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer
- First Posted Date
- 2024-12-16
- Last Posted Date
- 2024-12-16
- Target Recruit Count
- 25
- Registration Number
- NCT06734130
- Locations
- 🇺🇸
Moffitt Caner Center, Tampa, Florida, United States
A Phase Ib/II Trial of Neoadjuvant Zolbetuximab Plus Docetaxel, Oxaliplatin and S-1 Chemotherapy in Patients with Locally Advanced Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 57
- Registration Number
- NCT06732856
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- InSilico Medicine Hong Kong Limited
- Target Recruit Count
- 159
- Registration Number
- NCT06724042
In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial
- Conditions
- Interventions
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 40
- Registration Number
- NCT06704191
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
A Study of ASP-1929 Photoimmunotherapy in Combination with Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck with No Distant Metastases
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Rakuten Medical, Inc.
- Target Recruit Count
- 408
- Registration Number
- NCT06699212
- Locations
- 🇺🇸
Cancer Clinic, Lexington, Kentucky, United States
Mecapegfilgrastim Combined With Adebrelimab and Chemotherapy as Neoadjuvant Therapy in Resectable GC/GEJC
- Conditions
- Interventions
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2024-11-12
- Target Recruit Count
- 70
- Registration Number
- NCT06684158
- Locations
- 🇨🇳
The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China
A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours
- Conditions
- Interventions
- First Posted Date
- 2024-11-11
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- LaNova Medicines Limited
- Target Recruit Count
- 320
- Registration Number
- NCT06682780
- Locations
- 🇨🇳
FuDan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study of Ifinatamab Deruxtecan in Subjects With Advanced or Metastatic ESCC (IDeate-Esophageal01)
- Conditions
- Interventions
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 510
- Registration Number
- NCT06644781
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
- Conditions
- Interventions
- First Posted Date
- 2024-10-10
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 702
- Registration Number
- NCT06635824
- Locations
- 🇺🇸
Ocala Oncology Center P.L., Ocala, Florida, United States
🇺🇸Clinical Research Alliance, Westbury, New York, United States
🇯🇵Miyagi Cancer Center, Natori-shi, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.